ピカミロン
ピカミロン · 4-(ニコチンアミド)酪酸 · N-(3-カルボキシプロピル)ニコチンアミド · N-ニコチノイル-GABA · N-ニコチノイル-γ-アミノ酪酸 · Pikamilone · PIKAMILON · PICAMILON
識別子と物理属性
| CAS No. | 34562-97-5 |
|---|---|
| 分子式 | C10H12N2O3 |
| 平均分子量 | 208.21 g/mol |
| 単同位体質量 | 208.08479225 g/mol |
| SMILES | O=C(O)CCCNC(=O)c1cccnc1 |
| InChIKey | NAJVRARAUNYNDX-UHFFFAOYSA-N |
| PubChem CID | 60608 |
| ChEMBL | CHEMBL4303255 |
| EC No. | 609-002-1 |
| DTXSID | DTXSID40188098 |
| 現地名 | ピカミロン |
化学・物理的性質
| XLogP | -0.4 |
|---|---|
| 極性表面積 | 79.3 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 4 |
| 回転可能結合数 | 5 |
| 重原子数 | 15 |
| 形式電荷 | 0 |
| 複雑度 | 231 |
| 融点 | 211.0 to 215.0 °C |
| 沸点 | 522.4±30.0 °C(Predicted) |
| 密度 | 1.245 |
| 貯蔵条件 | Inert atmosphere,Room Temperature |
| 溶解度 | DMSO（微量、加熱）、メタノール（微量） |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | 4.60±0.10(Predicted) |
| 色 | ホワイトからオフホワイト |
| InChI | InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14) |
| InChIKey | NAJVRARAUNYNDX-UHFFFAOYSA-N |
| SMILES | C(O)(=O)CCCNC(C1=CC=CN=C1)=O |
| CAS データベース | 34562-97-5(CAS DataBase Reference) |
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%)Skin Irrit. 2 (100%)Eye Irrit. 2A (100%)STOT SE 3 (100%) |
| 税関コード | 2933599590 |
| 危険表示 | Xi |
| 危険等級 | IRRITANT |
用途
説明
Picamilon: an analogue of the neurotransmitter γ-aminobutyric acid (GABA)Picamilon is a derivative of γ-aminobutyric acid (GABA) and nicotinic acid developed in 1970 by the All-Union Vitamin Research Institute to increase central nervous system (CNS) levels of γ-aminobutyric acid (GABA). Drugs that can mimic or increase GABA activity in the brain have the potential to provide anti-anxiety and anti-convulsive effects. GABA itself, when consumed orally, does not cross the blood-brain barrier. Much research has, therefore, been devoted to developing orally active agents that have GABA-like effects. Both gabapentin (a GABA analogue) and picamilon were designed to be orally administered drugs that cross the blood-brain barrier and provide inhibitory CNS effects. Picamilon, prescribed in dosages from 50 mg to 200 mg, can cross the blood-brain barrier in animal models and, once in the CNS, is hydrolyzed into GABA and nicotinic acid. The released GABA could potentially have inhibitory properties, including anti-anxiety and anti-convulsant effects. Nicotinic acid would also be released, potentially leading to dilation of CNS blood vessels. The FDA has never approved picamilon for use in the USA, but picamilon is used in Russia to treat various neurological conditions[1].
使用
anti-cancer agent